<SEC-DOCUMENT>0001558370-22-004214.txt : 20220324
<SEC-HEADER>0001558370-22-004214.hdr.sgml : 20220324
<ACCEPTANCE-DATETIME>20220324081027
ACCESSION NUMBER:		0001558370-22-004214
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220324
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220324
DATE AS OF CHANGE:		20220324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gain Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001819411
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				851726310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40237
		FILM NUMBER:		22764745

	BUSINESS ADDRESS:	
		STREET 1:		4800 HAMPDEN LANE
		STREET 2:		SUITE 200
		CITY:			BETHESDA
		STATE:			MD
		ZIP:			20814
		BUSINESS PHONE:		(301) 500-1556

	MAIL ADDRESS:	
		STREET 1:		4800 HAMPDEN LANE
		STREET 2:		SUITE 200
		CITY:			BETHESDA
		STATE:			MD
		ZIP:			20814
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ganx-20220324x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/24/2022 11:15:50 AM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: eab8d1d5-6dd6-4893-97c3-000091fb368a -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ganx="http://www.gaintherapeutics.com/20220324" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:EntityCentralIndexKey" id="Tc_x7EV7NJAS0KUjtd9k8ALjQ_2_1">0001819411</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:AmendmentFlag" id="Tc_YkV0vTPdOkW-y9trkvor8w_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ganx-20220324.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-24</xbrli:startDate><xbrli:endDate>2022-03-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_65a86413_0bb4_4f10_9109_f7373ad75bb1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="font-size:11pt;">_______________</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:DocumentType" id="Narr_XvhWjRxanEuboTQaphGBfw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Date of report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_PJYRGldLEkSXZt8Qo_pMmA"><b style="font-weight:bold;">March 24, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:EntityRegistrantName" id="Narr_dIn_dbJNk0WwJPfgBRtc2Q"><b style="font-weight:bold;">Gain Therapeutics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of the Registrant as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><a id="_53a6d7d1_4bc7_4999_8442_a2d516ecf41c"></a><a id="Tc_a83z1xpRwEa5_iw8V6_Ghg_2_0"></a><a id="Tc_xbhloY2VgUe7HLd4C-3rOg_2_2"></a><a id="Tc_9mGDskvVx0iBGmYWAsZefQ_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.2%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.96%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.2%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_dV044tr8fUyKBFC_ggnXAA_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:25.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:EntityFileNumber" id="Tc_tsugVC1h80a8J0b-CJdhlg_1_2"><b style="font-size:9pt;font-weight:bold;">001-40237</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:EntityTaxIdentificationNumber" id="Tc_6c4048yZC0aF0UWyOE-fAw_1_4"><b style="font-size:9pt;font-weight:bold;">85-1726310</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:35.2%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or Other Jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Incorporation)</b></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:25.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b><br /><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:EntityAddressAddressLine1" id="Narr_LzUUXHYR0kK187Zt9YKGQQ"><b style="font-size:9pt;font-weight:bold;">4800 Montgomery Lane</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:EntityAddressAddressLine2" id="Narr_tMXtTbE9M02pDKvQW5pjPQ"><b style="font-size:9pt;font-weight:bold;">Suite 220</b></ix:nonNumeric></p><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:4pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:EntityAddressCityOrTown" id="Narr_4PAgzmS4dkO3Uroi1_TFuQ"><b style="font-size:9pt;font-weight:bold;">Bethesda</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_er4X3f1kDkuUPBweSPsxsw"><b style="font-size:9pt;font-weight:bold;">Maryland</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:EntityAddressPostalZipCode" id="Narr_Ghoe1kKGYEu92SmQsiVouA"><b style="font-size:9pt;font-weight:bold;">20814</b></ix:nonNumeric></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:0pt;padding-top:0pt;text-align:center;margin:0pt;">(<span style="font-size:10pt;">Address of principal executive offices) </span>(Zip Code)</p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:0pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:0pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:CityAreaCode" id="Narr_WrBAk0XZ8UGprsSlEFwgiA"><b style="font-size:9pt;font-weight:bold;">301</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:LocalPhoneNumber" id="Narr_O35SFhSR1Ua5U7pHVHsUzg"><b style="font-size:9pt;font-weight:bold;">500-1556</b></ix:nonNumeric></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:0pt;padding-top:0pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> (Registrant&#8217;s telephone number, including area code)</span></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:0pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:0pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:4pt;padding-top:0pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="white-space:pre-wrap;"> (Former Name or Former Address, if Changed Since Last Report)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 6pt 0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_ChZBkR0sE0mk48EYqrtr5w"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_LMxRniOKGUqfF2YNexd4GA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_1oaLFmODXEOCx4LKM7ZtNA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_UpvIRbSk50Ga-wSx49D8Qg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2fb5d649_c07e_44c5_a79a_54316551be21"></a><a id="Tc_zZXUmCC2dkyRF3lNXTnWRw_1_0"></a><a id="Tc_QbU52qp8s0uSHLkX-_IESA_1_1"></a><a id="Tc_DLLKm4QsKE6Xs4QmucxwGg_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.4%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:26.68%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.91%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.4%;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.12pt 1.5pt 1.12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">Title of each class:</b></p></td><td style="vertical-align:bottom;width:26.68%;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.12pt 1.5pt 1.12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">Trading symbol(s)</b></p></td><td style="vertical-align:bottom;width:36.91%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.12pt 1.5pt 1.12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">Name of exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.12pt 1.5pt 1.12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:Security12bTitle" id="Tc_2pSzTzsm5kal8-ovynHSiw_2_0"><span style="color:#212529;font-size:9pt;">Common Stock, $0.0001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:26.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.12pt 1.5pt 1.12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" name="dei:TradingSymbol" id="Tc_XGkPDdrtMEeDYD9EC241Zw_2_1"><span style="color:#212529;font-size:9pt;">GANX</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:36.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.12pt 1.5pt 1.12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc__42RJCnrDUaU7ImrqkvI6A_2_2"><span style="color:#212529;font-size:9pt;">NASDAQ Global Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:0pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:3pt;padding-top:0pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_CvrmJHrKE0mDagoJqSPxKw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><ix:nonNumeric contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_L5xSyVwZZ0m1d-BMoD9w6w"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_258bc349_9ed0_458f_8c84_ca60d5ed7976"></a><a id="_Hlk71468351"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><b style="font-weight:bold;">Item 2.02. </b><b style="font-weight:bold;">Results of Operations.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 24, 2022, Gain Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the year ended December 31, 2021, and business update. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed &quot;filed&quot; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, &#160;nor shall such information and exhibit be deemed incorporated by reference into any of the Company&#8217;s filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:22.15pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01. </b></span><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:22.15pt;margin:0pt;"><span style="white-space:pre-wrap;"> (d) </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibits</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.2pt;margin:6.59pt 0pt 0pt 0pt;">The exhibits listed below are furnished as part of this Current Report on Form 8-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:12.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:12.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.2pt;margin:1.29pt 0pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ganx-20220324xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Gain Therapeutics, Inc. Press release dated March 24, 2022</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.64pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f42d46ce_69cb_418e_94ab_955e91bef803"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SIGNATURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GAIN THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:46.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eric I Richman</p></td></tr><tr><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eric I. Richman</p></td></tr><tr><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;">Date: March 24, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6.09pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ganx-20220324xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/24/2022 11:16:09 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:11.99%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:14pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;"><img src="ganx-20220324xex99d1002.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87pt;"></b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:14pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">Gain Therapeutics, Inc. Reports Full Year 2021</b><font style="font-size:14pt;">&#160;</font><font style="font-size:14pt;"><br></font><b style="font-size:14pt;font-weight:bold;">Financial Results and Business Update</b><font style="font-size:14pt;">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 0pt 36pt;"><i style="font-style:italic;">$36.88 Million in Cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash position to transition the Company&#8217;s lead program into clinical trials</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 0pt 36pt;">---&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Compelling preclinical data presented on lead program GBA1 Parkinson&#8217;s Disease at multiple scientific conferences supports transition to clinical stage company with FIH trial by year end</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 0pt 36pt;">---&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 0pt 36pt;"><i style="font-style:italic;">Entered into multi-target deal with Zentalis Pharmaceuticals to identify novel small molecules for oncology indications</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">BETHESDA, MD, March 24, 2022 (GlobeNewswire) &#8211; Gain Therapeutics, Inc. (Nasdaq: GANX) (&#8220;Gain&#8221;, or the &#8220;Company&#8221;), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced its financial results for the full year ended December 31, 2021 and highlighted recent corporate accomplishments.&#160;&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">&#8220;Gain finished an extraordinary year of building value and accelerating its lead program to the clinic to provide a potentially disease modifying treatment for patients suffering from GBA1 Parkinson&#8217;s Disease,&#8221; commented Eric Richman, Chief Executive Officer of Gain. &#8220;This program as well as our other programs in our R&amp;D pipeline provide tangible validation of our strategy to target novel allosteric binding sites with small molecules identified with SEE-Tx, our supercomputer-powered computational target and drug discovery platform.&#8221;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;"><b style="font-weight:bold;">Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Hosted Research and Development Day &#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;text-align:justify;">Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable&#8221;</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:14.2pt;text-align:justify;text-indent:-14.2pt;margin:0pt 0pt 0pt 28.34pt;"><font style="font-size:9pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Presented preclinical data on its structurally targeted allosteric regulators in GBA1 Gaucher disease at the 2022 World Symposium held on February 7-11 in San Diego, California. The data generated in GD-iPSC-derived dopaminergic neurons show that the administration of the tested compounds leads to an increase the GCase enzyme levels and enables trafficking of the enzyme to the lysosome, where the enzyme depletes the toxic substrate glucosylceramide as well as phosphorylated alpha-synuclein and increases autophagic flux.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:14.2pt;text-align:justify;text-indent:-14.2pt;margin:0pt 0pt 0pt 28.34pt;"><font style="font-size:9pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Progressed IP portfolio with published patent applications for lead compounds in GBA1 program (Gaucher disease and Parkinson&#8217;s disease), GALC program (Krabbe disease), and PCT filing for IDUA program (Mucopolysaccharidosis Type 1).&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:14.2pt;text-indent:-14.2pt;margin:0pt 0pt 0pt 28.34pt;"><font style="color:#25606c;font-size:9pt;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">Strong cash position to advance the Company&#8217;s programs. </b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">As of December 31, 2021, the Company&#8217;s cash position was $36.88 million, compared to $7.49 million as of December 31, 2020.&#160;&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 21.3pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 21.3pt;"><b style="font-weight:bold;">Upcoming 2022 Milestones</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 21.3pt;"><font style="font-size:9pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Complete the preclinical development and submit the regulatory dossier to the Human Research Ethics Committee in Australia to initiate a first-in-human (FIH) Phase 1 clinical trial in its GBA1 Parkinson&#8217;s disease program.&#160;</font></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">1</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:11.99%;margin-top:30pt;page-break-after:always;width:82.13%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:11.99%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><b style="font-size:14pt;font-weight:bold;"><img src="ganx-20220324xex99d1002.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87pt;"></b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Advance its GBA1 Gaucher disease program into regulatory toxicology studies; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Announce data from new internally developed allosteric regulator programs; and&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Continue to progress its research and discovery programs originating from its SEE-Tx platform across a range of indications, including lysosomal storage diseases (GM1 gangliosidosis and Krabbe), genetically driven metabolic disorders (liver and lung disease) and oncology.&#160;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 21.3pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 21.3pt;"><b style="font-weight:bold;">Full Year 2021 Financial Results</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 21.3pt;"><font style="font-size:9pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 21.3pt;"><b style="font-weight:bold;">For the year-ended December 31, 2021, as compared to the year-ended December 31, 2020:</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 21.3pt;"><font style="font-size:9pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Revenues were $165 thousand compared to $29 thousand.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Research and development expenses were $7,164 thousand compared to $2,259 thousand.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">General and administrative expenses were $6,827 thousand compared to $1,249 thousand.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Total operating expenses were $13,991 thousand compared to $3,508 thousand. Operating expenses include the impact of non-cash stock-based compensation and warrants for $1,873 thousand, compared to $82 thousand.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Net loss was $13,891 thousand compared to $3,578 thousand.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">GAAP basic and diluted net loss per share was $1.37, compared to basic and diluted net loss per share of $1.33.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">Revenues were $165 thousand for the year ended December 31, 2021, compared to $29 thousand for the same period of 2020. The increase was primarily attributable to a program initiation fee and development services on the first target development program identified under the Zentalis Pharmaceuticals collaboration agreement.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">Research and development expenses of $7,164 thousand for the year ended December 31, 2021, compared to $2,259 thousand for the same period of 2020, an increase of $4,905 thousand. The increase in research and development expenses was primarily driven by increased program development activities related to the advancement of the Company&#8217;s pre-clinical pipeline, as well as increased personnel-related costs resulting from an increase in employee headcount and the impact of non-cash stock-based compensation that amounted to $344 thousand and $57 thousand as of December 31, 2021, and 2020, respectively.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">General and administrative expenses were $6,827 thousand for the year-ended December 31, 2021, compared to $1,249 thousand for the same period of 2020, an increase of $5,578 thousand. This increase was primarily due to increase in expenses for legal fees relating to patent and corporate matters, professional fees for accounting and investor relations as we continue to expand our business and build management infrastructure an increase in personnel-related costs resulting from an increase in employee headcount and the impact of non-cash stock-based compensation that amounted to $495 thousand and $25 thousand and warrants of $1,034 thousand and nil as of December 31, 2021 and 2020, respectively.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">As a result of the above, net loss was $13,891 thousand, or&#8239;$1.37 per share basic and diluted, for the year-ended December 31, 2021, compared to $3,578 thousand or&#8239;$1.33 per share basic and diluted, for the same period of 2020. The increase in net loss was due to increased research and development expenses, as well as an increase in general and administrative expenses primarily related to investments in the Company&#8217;s infrastructure as a publicly traded company.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 21.3pt;">Cash and cash equivalents were $36.88 million as of December 31, 2021, compared to $7.49 million on December 31, 2020.&#160;&#160;&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:11.99%;margin-top:30pt;page-break-after:always;width:82.13%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:11.99%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><b style="font-size:14pt;font-weight:bold;"><img src="ganx-20220324xex99d1002.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87pt;"></b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED BALANCE SHEETS</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 36,880,673</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7,492,910</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 11,371</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 8,548</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 113,586</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 58,017</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 727,785</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 198,994</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,217,988</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 37,722,044</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 8,987,828</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 105,986</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 29,633</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Internal-use software</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 202,609</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease - right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 901,042</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 523,080</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 31,279</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term deposits and other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 22,111</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 63,817</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total non-current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,263,027</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 616,530</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 38,985,071</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 9,604,358</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholder&#39;s equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 560,479</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 961,516</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liability - current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 219,137</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 122,756</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,402,600</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 768,450</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 266,504</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 239,483</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loans - short term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 103,826</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 22,626</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,552,546</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,114,831</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Defined benefit pension plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 329,458</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 171,558</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liability - non-current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 695,053</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 400,324</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loans - long term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 590,468</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 715,656</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total non-current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,614,979</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,287,538</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 4,167,525</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,402,369</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Series A Preferred Stock, $0.0001 par value: nil and 1,185,879 shares issued and outstanding as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 118</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Series B Preferred Stock, $0.0001 par value: nil and 2,965,600 shares issued and outstanding as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 297</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common Stock, $0.0001 par value: 50,000,000 shares authorized; 11,883,368 and 3,543,163 issued and outstanding as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,189</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 354</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 55,832,461</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 13,388,771</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (90,645)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (152,698)</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (7,034,853)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,457,171)</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss of the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (13,890,606)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,577,682)</font></p></td></tr><tr><td style="vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 34,817,546</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 6,201,989</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 38,985,071</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 9,604,358</font></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:11.99%;margin-top:30pt;page-break-after:always;width:82.13%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:11.99%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><b style="font-size:14pt;font-weight:bold;"><img src="ganx-20220324xex99d1002.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87pt;"></b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain Therapeutics, Inc</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 133,928</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 31,066</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 28,881</font></p></td></tr><tr><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 164,994</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 28,881</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (7,164,229)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,259,204)</font></p></td></tr><tr><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (6,826,938)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,249,126)</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (13,991,167)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,508,330)</font></p></td></tr><tr><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (13,826,173)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,479,449)</font></p></td></tr><tr><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 12,495</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,637</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign exchange loss, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (72,920)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (96,484)</font></p></td></tr><tr><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (13,886,598)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,572,296)</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (4,008)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,386)</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (13,890,606)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,577,682)</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per shares:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders - basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1.37)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1.33)</font></p></td></tr><tr><td style="vertical-align:top;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 10,165,404</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,681,408</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">About Gain Therapeutics, Inc.&#160;</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Gain Therapeutics, Inc. is transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform SEE-Tx&#174;. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas provides opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition and allosteric activation. Gain&#8217;s pipeline spans neurodegenerative diseases, lysosomal storage disorders, metabolic diseases and oncology. Gain&#8217;s lead program in Parkinson&#8217;s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson&#8217;s Research (MJFF) and The Silverstein Foundation for Parkinson&#8217;s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. For more information, please visit https://www.gaintherapeutics.com&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For more information, please visit&#8239;https://www.gaintherapeutics.com&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Cautionary Note Regarding Forward-Looking Statements&#8239;</font>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">This press release contains &quot;forward-looking statements.&quot; In some cases, you can identify these statements by forward-looking words such as &quot;may,&quot; &quot;might,&quot; &quot;will,&quot; &quot;should,&quot; &quot;expect,&quot; &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;predict,&quot; &quot;potential&quot; or &quot;continue,&quot; the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company&#39;s belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company&#39;s control. It is possible that actual results,&#8239;including with respect to any financial forecast or the possibility of any future regulatory approval&#8239;or filing, may differ materially from those anticipated in these forward-looking statements due to a number of factors, including but not limited to, risks detailed in the </i><i style="font-style:italic;">most recent Annual or Quarterly report, as well as </i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:11.99%;margin-top:30pt;page-break-after:always;width:82.13%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:11.99%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><b style="font-size:14pt;font-weight:bold;"><img src="ganx-20220324xex99d1002.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:42pt;width:87pt;"></b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">discussion of potential risks, uncertainties and other important factors in Gain Therapeutics&#8217;s subsequent filings with the Securities and Exchange Commission</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">New risks and uncertainties arise over time, and it is not possible for us to predict all such factors or how they may affect us. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We are under no duty to update any of these forward-looking statements after the date of this earnings release to conform these statements to actual results or revised expectations. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this earnings release.</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Investor &amp; Media Contacts:</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gain Therapeutics Investor Contact:&#160;<br>Daniel Ferry&#160;<br>LifeSci Advisors&#160;<br>+1 (617) 430-7576&#160;<br>daniel@lifesciadvisors.com&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gain Therapeutics Media Contact:&#160;<br>Joleen Schultz&#160;<br>Joleen Schultz &amp; Associates&#160;<br>+1 760-271-8150&#160;<br>joleen@joleenschultzassociates.com<font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:11.99%;margin-top:30pt;page-break-after:avoid;width:82.13%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ganx-20220324xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20220324xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #8 < # 2(  A$! Q$!_\0
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MO&+7.J7LN>S3L1^6:H[:-M:J*6QRRJ2ENQK%G.78L?4G-20W-Q;G,-Q+&?\
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MD$4M<IZ85P7Q%\17WAJ^T.\LVR"TPEB8_+*OR<'^A[5WM>6_&49AT;_>F_\
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M''49\M/R'/ZUUFGZ-INE(%L;&"#'\2(-Q^IZFM7570Y(82;^)V*WAG4+K4]
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MNN5GOQ^%!7"_$@9CTWZR?^RUW5</\11F/3OK)_[+54_B,<5_!?\ 74\^VU)
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MU=17,^.AG0H_^OA?_06IP^)$8C^%(\VVT;:DVT;:Z3PSV'3/^039_P#7!/\
MT$5:JKIO_(*L_P#K@G_H(JU7(SZ"/PH*XGXAC,>G_63_ -EKMJXOX@#*:?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDD<N'G*4I7?4P?%VLW.A:,MW:+&TAE5,2 D8(/H1Z5P__"R=;_YXV7_?MO\
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E6M:NFH:C'*EN)!+)),,-*<YP >H/K115S]U:&%"]:?ON]C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ganx-20220324.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/24/2022 11:15:54 AM-->
<!--Modified on: 3/24/2022 11:15:54 AM-->
<xsd:schema targetNamespace="http://www.gaintherapeutics.com/20220324" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ganx="http://www.gaintherapeutics.com/20220324" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ganx-20220324_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ganx-20220324_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ganx-20220324_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>ganx-20220324_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/24/2022 11:15:54 AM-->
<!--Modified on: 3/24/2022 11:15:54 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.gaintherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="ganx-20220324.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ganx-20220324_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/24/2022 11:15:54 AM-->
<!--Modified on: 3/24/2022 11:15:54 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document information [Line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ganx-20220324_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/24/2022 11:15:54 AM-->
<!--Modified on: 3/24/2022 11:15:54 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="ganx-20220324.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637837173542993775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_DocumentType_637837173542993775" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637837173542993775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_DocumentPeriodEndDate_637837173542993775" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637837173542993775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityFileNumber_637837173542993775" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637837173542993775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityRegistrantName_637837173542993775" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637837173542993775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityIncorporationStateCountryCode_637837173542993775" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637837173542993775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityTaxIdentificationNumber_637837173542993775" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637837173542993775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityAddressAddressLine1_637837173542993775" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637837173542993775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityAddressAddressLine2_637837173542993775" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637837173543003810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityAddressCityOrTown_637837173543003810" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637837173543003810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityAddressStateOrProvince_637837173543003810" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637837173543003810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityAddressPostalZipCode_637837173543003810" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637837173543003810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_CityAreaCode_637837173543003810" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637837173543003810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_LocalPhoneNumber_637837173543003810" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637837173543003810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_WrittenCommunications_637837173543003810" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637837173543003810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_SolicitingMaterial_637837173543003810" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637837173543003810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_PreCommencementTenderOffer_637837173543003810" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637837173543003810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_PreCommencementIssuerTenderOffer_637837173543003810" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637837173543003810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_Security12bTitle_637837173543003810" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637837173543003810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_TradingSymbol_637837173543003810" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637837173543003810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_SecurityExchangeName_637837173543003810" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637837173543013775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityEmergingGrowthCompany_637837173543013775" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637837173543013775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityExTransitionPeriod_637837173543013775" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637837173543013775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityCentralIndexKey_637837173543013775" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637837173543013775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_AmendmentFlag_637837173543013775" order="24" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139962692260344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity information<br></strong></div></th>
<th class="th"><div>Mar. 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 24,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gain Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1726310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4800 Montgomery Lane<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bethesda<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">500-1556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GANX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ganx-20220324x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ganx-20220324.xsd" xlink:type="simple"/>
    <context id="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Tc_x7EV7NJAS0KUjtd9k8ALjQ_2_1">0001819411</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Tc_YkV0vTPdOkW-y9trkvor8w_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_XvhWjRxanEuboTQaphGBfw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_PJYRGldLEkSXZt8Qo_pMmA">2022-03-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_dIn_dbJNk0WwJPfgBRtc2Q">Gain Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Tc_dV044tr8fUyKBFC_ggnXAA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Tc_tsugVC1h80a8J0b-CJdhlg_1_2">001-40237</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Tc_6c4048yZC0aF0UWyOE-fAw_1_4">85-1726310</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_LzUUXHYR0kK187Zt9YKGQQ">4800 Montgomery Lane</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_tMXtTbE9M02pDKvQW5pjPQ">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_4PAgzmS4dkO3Uroi1_TFuQ">Bethesda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_er4X3f1kDkuUPBweSPsxsw">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_Ghoe1kKGYEu92SmQsiVouA">20814</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_WrBAk0XZ8UGprsSlEFwgiA">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_O35SFhSR1Ua5U7pHVHsUzg">500-1556</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_ChZBkR0sE0mk48EYqrtr5w">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_LMxRniOKGUqfF2YNexd4GA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_1oaLFmODXEOCx4LKM7ZtNA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_UpvIRbSk50Ga-wSx49D8Qg">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Tc_2pSzTzsm5kal8-ovynHSiw_2_0">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Tc_XGkPDdrtMEeDYD9EC241Zw_2_1">GANX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Tc__42RJCnrDUaU7ImrqkvI6A_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_CvrmJHrKE0mDagoJqSPxKw">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A"
      id="Narr_L5xSyVwZZ0m1d-BMoD9w6w">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M='@//GL?)=-[*CG_5U/\!%!+ P04    " !,07A4EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( $Q!>%1>E\GE/P$
M #P"   /    >&PO=V]R:V)O;VLN>&ULC5%=;\(P#/PK47[ 6M"&-$1Y&?M
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M?P%02P$"% ,4    " !,07A4!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $Q!>%1Z'=YW[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( $Q!>%297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ 3$%X5%36#Q=I!   EA$  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( $Q!>%2?H!OPL0(  .(,   -              "  :P,  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ 3$%X5)>*NQS     $P(   L
M ( !B \  %]R96QS+RYR96QS4$L! A0#%     @ 3$%X5%Z7R>4_ 0  / (
M  \              ( !<1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M $Q!>%0D'INBK0   /@!   :              "  =T1  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $Q!>%1ED'F2&0$  ,\#   3
M              "  <(2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(   P4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ganx-20220324x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ganx-20220324x8k.htm">ganx-20220324x8k.htm</File>
    <File>ganx-20220324.xsd</File>
    <File>ganx-20220324_def.xml</File>
    <File>ganx-20220324_lab.xml</File>
    <File>ganx-20220324_pre.xml</File>
    <File>ganx-20220324xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ganx-20220324x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "ganx-20220324_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ganx-20220324x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ganx-20220324_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ganx-20220324_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ganx-20220324.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ganx",
   "nsuri": "http://www.gaintherapeutics.com/20220324",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20220324x8k.htm",
      "contextRef": "Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity information",
     "role": "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20220324x8k.htm",
      "contextRef": "Duration_3_24_2022_To_3_24_2022_fbGgCnieCU27AZ_wul3P_A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-22-004214-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-004214-xbrl.zip
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MC?'W_HD$?(#-?-;G;*1H,*Y^ %!+ P04    " !,07A4I!O1E.X"   N"P
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M5HBX-US2K6:0'A##-+HFT4>QB:AHM*QK %K:ULJ,%426PZ;/NC=UF:VX/HQ
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MX1"P/M"$!_%?>%*Y[3>(FP*JMDDMI@5E$R#5!WXM1#-W$/9U;N/E G[%4&!
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M!)^3T+BHB:+X,C;XP/]=5LCD]8B-FLRWA*@N"%&#U^XM%H359&?NX%+I$VO
M*Z[P"!QB<$)87M/TI\@DKC]A8+*'#'I4%(Y1%^819-8)0(!#XMD ?NBCP!F.
MW1#"4G\<N#,4@&X.NC/^9OR";P)IH^Q$7.%%;RN\QM /1=B;)<^ZO@N#L_>8
MD^ZP;%E06DN]UV-3F^PTBK97":;K6X.(3QR/)5S2Q4K%32U"FK[OFAC($\(D
MI0W:%^J$,",LOSCVXDQ0D+)JE?[UP: A!35I.-"*M:_?:4CUR2+!3:C:)#V?
MH'8=-6=#L&MW>2JZB@44@'0SAC"^Q23=*&C:K:3?-8;1[8>UQ]9^C!F0,XT:
M&J4JDAMCER!-T6-68CR4*O)EM;W;<@%5#AM(4241&JY6Q/Y8IFKZKF,!$;W>
M*>@%4 YN.K5U.FUXSOGQ4?M[]U#Y>D:FMG94_ATXZA8M-(SQNL].LH8%64EQ
M5*96?,Y/FB1&+=]8:BF6NJ"$Z2BVIX]O^&!&A)YWNQD77/;QR>'PO'I5.Z],
MM9/CT\)U>/9;L!:@)U@I_)[46K)F"\JV^7XY1HO:OK':S[!:/0C&A"YFN/;H
MIMXPFP-=.L+"I#G5C&KQLO=G,IQ*!&W;6H[AXK;K]$BS&W(BMY!0<"Q'B[8<
M<5&)W42 =CU>X4^N:,5E_TK7U.V\9G0LJ4 ZFF;I'5PP<$?75#FOZ[))E&27
MZKQ$_\?U57M8J2CV8-8X5-VSJY;WI3&)B\(R+2_-MJY\'Q4#:=S\>#*X$CKU
M6I.5C]WKLWIR<CS4+H/C6OXJT"Z'8VLZ.4JJA?[PLO^\J+U5A?Z"\O.\F"^^
M$?X7E$'G1>.M#OJ7UD%SE1-KT>A\A-$4 ?Z.C?Z1^%\J<[?@X4-SQTXE4OC'
M[<7*RG:67K$ <^#3TC^*K.B*L2CEW6)'NT3;4:T^LEP<L)3-\^N58A7R%Q.2
M8IX7#[A?N1W\5-57K ^6HF)\<,=?1>1DKRE)/%_P+2=]!SCWU@%=4$+UD^H@
MUHT/DOBWX/)?7FX51PDS63&YLIF7,RNCYH_6CV"H#[!;%/R;F?>QZ4SB/;-I
MP[" +5*1%(L5@0V:(02U.^C_))$=[(-&F*(;[([)@S':2_3;&V>L@C-BE1E%
MXG.VN#H:7%1M&I[62/5KU:A5%$V^GD0G<3V#+8[*9U<KFONL5G[9W/\>6ON5
M;-UB:OY^K5>B4)+TQ^WY"L ]'4UI?*IXM-K&[4)]2+\/;NKY<KR]?GGN.2LW
MJ^5+=.3Z)G;1*:8#$C[)3:^Z7'?E990/U"9D(*Y[-LMH$63.D,77+.'Q $PV
MX?LO[BPH.@$"_ B0M<<\J1[U)V&?)<9&;)$1!\@F7<>+CI.(EHXD/4DJW5DW
MBLZ$4=$VJVDO[/+EHZ0Q# .,,V*'4; EWBB[IIB"LJ"O10?-S#MEF;;;]U+=
MBBM,;]TAL?K0(GB<R57S2\98$9_7'B!VPD*_, T<U2\F !YQ^"H1>.GUT1LZ
M_/21'M>D817W_$_?FQ?3XY>LC\;)W?S#R=V-GE\2@53O/B(9K"IGH9@Y]Y;L
M^R!$Q"46.QK7\WF*=AP0W@KF-2X,8(>:\D0 BHXB9%/&QW)G;'!V>B]?]?<
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M"C9B2F\8\=@->(H18Z#_4C*EM,+E.! .2T-1B >)DQB7) YPYZ$(8?[14(@
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M]MZR41!CR-YM& :V= 7!_ 5G$P'A+@P;XC>/TR;"T61\^6J"[/:BP;]>G3=
M2" >A@!0^#"7\, $1B@QGP>D3,5M@A!Q--29(6S V#6-9?$J1*=1&ED"RG,2
M5"#-)L5T)"Y. D'XY+MS_(EY?\UG#)X"9Y) 2.:A<,L$%$;EW]%0IXVG#Z?8
M(L6:3".W,%FL^(3#?)<E>!8?OP,BPGB4Q-EDXL:V".<N!/Q (T*2^\#>GXH0
M_@1SER9L\J>T$<Z]V'893!..+R,BE*LS<!^G:.S&=\V-:7?E )0#4 Z@I@X
M\#^$DV L/GPEF#H?"Y>+!('[\<A-$BL^Q9P'H;[O9KE8F=^0.9-[8YDY@"SE
M\&+%$X !6DU[I'=?:N3=V<?S^[?_.Z"C$2O<EJ^?7Y,QERL+.((/%W^<W;_Q
M"4RC+\"R4ALK+K@#3B8DUW.?$>-E\Y'5Q:,S<SO;-,S,!X-?S'9'[]C#10NW
MDE)0)D^9O-SDC9Y!XZ34K=6WJPWKO]2YP5*TM8N_68:T2=97!3R_U3C;M!J^
M;OB+M-Y"C)BNL<^2-78M67K!="I,Q*_=9JN?W=JP[*XW%U<@CLB:&ANLY),E
M=G?.XO[A UO11TK0]8D#(HF$QV0J=Z^CW.0X\E&J6%@YAFK$PF@Z$79+.[J0
M#RFDBC$$!2P^XTD6(<]^S G$FB$',YG"^_<QC/8^Y7P93;D=HGF&5R/&,%8^
MBQ'2NYS*D@@/3+1<]87P-@@Q.FM,91LOWGYX_Q*K*"" -I9*C[ 93--L6%#,
MXN[4B34?,Y$/5U86!5E6(S]Q^>]BD8K9*MB7AVLL37G7*!J%A++D[VF0JSRU
MOT\"!"^--*;5Y7_# MV+-]+J5.Q!UJRFO^OKIJ=HSI)"[/3*0AWV<HFW3R>L
M,0H8_=Z@8Z!_0-U;.@^S6EBS:5B9#4@K7?65RNUG*@A_"OXO.1.KP&U5OYSP
M1#DXY>!V @XIS,D=QG)Z9J'&M>#:9 HZ65H,H]CA+!R2S4Y$B:<2SYW$,ZVL
M2]9W9)V4!]UR# *\I-PJ"<0V+$#E4'V(4=ICH8Z24B6ENZ$$+^)>S-*B0)D]
MEQ8U*%:7%(K/L@H[ <$6]Y)Z0RG<^%)2Y)97J!%J!P C  ,$U)LP3+\4RI\U
M7+QS8UE(M[92-5G7>_'NDT$@[)FX'**') 6.8TK2Z2\U&<AD08V#"Z8>P4V*
M$#J!.N4%K^2%R[&&5M;%QMXDS\,GU;AI>?:CD.*8LBZ+VYW(REZC8\B^')H%
M:?DU5OXV-E1>:YC9+*8]'WE!'QP#XY1#W(-#-(_/(7Z#H S\(1:A!(S\:G3:
MH$\B#M%++*PMF/W\QGYK3<R?&K\*%)5>/(U>%./!0@J9W?G,"W.%Z6I&I[5)
M932SK;1&:<WQ:,T[F61UDRU:A1+-&[:L-QVM9W8WZ(VAF2VE-TIOCD=OKD4$
M6B/\;$?CDK(8EM;O&QNTQ=+:>N]>6\B7U5:2Q$.R-,KA53O"W(0GO(8L, DC
M87]OC&B8UD[#2TE9-?9U2X. >NG66%#-7M?*.ULJ/^F92FF5TAZ-TGYF$7$Q
MWR?KLD!'>P_I:+>GE$,IQ]$HQ[NSLZ\$7 JWTXRZ&^.>%B_3&7!2))R"@J3:
MT[2ZB]YDJW?!B^&K5I4TZM#;L _2_T-IIG$AZ;OIN UM8S(J?SVD,X:BP863
M'ARE)QO.\HU?*&E^P&&<0#*A413P49P8."PC+BR@RV(NC(#&C*UD &!";C@>
M5Y0>."4+ODA^@L[]@WE[]V<CQ$!>,MR-!^Q(2SD2Z<XV.@D8P]::AV;AH?M_
M/".#UF I'[.+;"UD;1X2+VUA6R'VWM+Z>KL0BR^('_>65AG79I469#1=WQO-
M\U;N#SE9J&NT 6.#T.)9:BS9/9@NC*3%\?*I="/C:HT\:^1UB=G1(5IQ8V*A
M<Q:$PO.8V\CZL468+)_B.5+9XFAQ7H!L-O-=,0=5PG-2;1&GE9@_"D?D[D\Z
MP_>SN*I5X#7^^;5=2"IL/'@.;R8,A''[#">/N?-2:MAJC>-8_K=['+7#P'9.
MZXRW6L][(/GS8^K77@RSB3Q!9X/Y=Y(B@ 4QS6A)-L=-@&*P_ZE*R>.!1+Z7
M3D;XV5%/,_ E\I IT,TQ'N\@CW20[V)3>!)4[$7945C<N\%Z_B!M%W?C25W#
MH_#RX@08BURHCP,RRHZWQ OR+"3HT*.31*FY-PYHML^;+6M>R?2UU6\OZ:NY
M="%/-\C03M.M)07WN+M)KZNDUL_9_YFL2)$,SUP Q!<W8.*]AQ LG@*'/L+J
M#V5X7@B[5V)S;1=-7P3%B[U9V_7V>,PG3XTK4+FD]L[C+GG!$RXIRF0+PWAO
M<@JN.;$!\GPF;&>=6UY6;.2BW--KXUD. 752=8-WCE[$DW-FT2;C#^S?,;^A
MKIS<Q"TM;)K;'!=LWDP'_S^\DZXP [7:AF&J;1AJ&T8=MV$\SS'R#Q6[;3B@
M=<_?.OB9$9Y_^7SUY>.'B[/KRPORYNSCV>?S2W+U_O+R^BH?I61#DD39*O6;
MC P%/^4Q,@LC7QC<@K*CW"SJNKRRH(CZ?8(T?6;9HA)).DB'I%VF>+-Q9A_#
M2%._>3)U.5,KLHQL5V^:N?TI]IW-94$:"XUC)?'8%;=9_5[V>P.3O8/$2-W"
MG#UJ._+[=!0*C(2&6=K[:6W( TYB^P+%HN]8REXO37AB_1](C#>[!V1"8>UA
ME1^*#XH/!^"#WE&,* ,CC&9;J40I.*%,4TGXH$Q3.1BA-_N*$?MCA%S17ZP6
MV<"1[9##\U'=6X?UMYV&IS3*/ST%O949> C;KB;OLA3>Z(B)!:P.Q !>-D]V
M)=QL=EI/3OK/9#6R1&XR!9:A*<;OA?%&L_^@LZ\&XY5E+Y_,JREXWBG8FQ=(
M4\%I^&?X=P1B/NZ0;"&HQ,8B_^2IDHVG<135E@W]4:^QNBQJVXR-QRN5X-NO
M+SS]9Z47Z3P+0U;X@-22%FQ+8 G5X_&021'])$0_G YZ%DOX\Z'!WJ;CL7SQ
MWE> Y1KICO!!:832B"?7B$?2E"56B,=QXV$=_7D<!+)R6?KT027#VF*1W?$.
M_; 6XWG0=!D\XVIAIY*Y.LM<"7S/>I&K)KC,RXP[_H,EVO6**3?K7'5I*G7$
M^/RFZ==Z8T)B-=N;-P@4!XX;1^703UX3JZ/U>KK6Z5K/PG2E C56@4,[XMTT
MH*NU^J;6-_05EI<:&BZYZ6\LC )NRYVBX*B//>X]J)UYIH7+9[<>^^-/19VE
MW.-IUF?U60EJ/5V:86A6U]C&GU4/CYXEAS+@40@V RPZ<EF]0M;:(]&CB[J?
M@:.U=:A*YI7,U\HW][1VJU=IJ'E-[X@=,(>OSP$?@V(J&LM@8XYQ?7-70&!I
M[5Y'2;22Z'IXT79/TXUN/1'NUX#YE#OW)Y')4]8B_&2LO5 ,5*]X6>%>A0&.
M!?=VS:[6[;45[E4R?RRXU^CWM'Z_56GD>\'&+,!S)L48?L!3>.6IO)6,I]5B
M:[D-R<' [0'W]ZE5V_((PU%(O'2EM1-X0S.-KM;O;95FK@ ^'F8?VE/PMUHT
M'3<4>(YZX]K9+@N L6EJ>FL5*2B-4!IQ?,X<4'.OJ_7,BJT9+Y,G'SRVTWT4
MC0J-E"Z9?6@JE;C6A,AGR4/OA\C*XM[/^+&VQT^ J&Y K&!OW8+\8UCUS<E4
MXJO$MW(+N!NEM]2(<J5*2O@PMKFLCL)C*>37'^6W,2L9I:KUV*K:A<IYKQU7
ME?2VUE<UQ$<DJ(?V4[O)J=G7.M;J:2;5A(!+3N\#'GCLP<#BD)%0C*-;&M1L
M^VNIHL^C)KZ*.:SZ0,P=C9]N:AV]KY1#*4>- >Q^ZP"KA'J_^/@5;JP\=AF%
M&*!!Y-P0,288$FPNC"J]=BO\6V[[<_3XMZ\;FMXR%?X]&D&MIIMKFY:F][8Z
MS;!Z 'B+8PZK&^"JQ:2Z!>W'L!:Z8YVOH9E=A5.5R"OX62'X^5%XDT;$@AEQ
MF/P@>/%P"F^E5JF20;("HE4U,$?B.DU3,XS5TUV5G-953JOI[SJ6UJO-$4W#
M; OJ=DZNNL&KPJ!U"\C+1'U--ZT"E@5KIYNKUDZICU(?M</UD4#!Z&AMJV*?
MW\D# H5T*VJ3RF]ZUFZ7WX?+M<!H."(>N:RZ5L/"C?%M35_SG1,EQS64XS6^
MKPYBW-<Z>DNSVC4ZJZE,$5,5%5H1KY!"Y5>%2S8?2A6.EOI#9\]_9CK*#H%?
MC1;:+)[O=/+Z(Z>23IY^PB",A/U]"O=8\-LO5G\8RFV[T?S5Z4@%[XK&:INK
M<CKH0U.IQ+4F1*JSGIZ>XO-T6=F]]YLU.^SIP7 ART:O#P8J3'11D%?H/CIH
M< PET=N)NA)X)?#U@;B[R7NI >ZF+\_[=+[IL_.E5TZUYEMN:[''-=_*K86U
M.[K6>G!3D)+1VLCHH7W6CLNU'4-K&ZN'H%43=#YRN$0&1.>DD7UZIUZ1JBIV
M5L%V]=#ECKN&C+YF6*I"6<E\!0'FCF7YIJEUVULYZ_+ZY(7OOA=2PY4,CQ7Z
MK*HI.1(O:6@M>8+BZFX$):IU%=5J.K=NIZ>UVC4]YBG_T#KW;#&KV0G'"G6J
M"/QH4&>GH[5U]2U7)?-'@SI-JZ^U>EM]@*"T_O>CH%Y(&B2<BB B>.!3)0-A
M!3?+;4,.5G=;NSWTAFYI/5-]G$=)_)$<&F&:6F>-O%<3_0ZSPR2VS/-6-V96
MV+=N.*!,U%<5)&OM-OQI/>2^E7HH]3A2/*T91DOK6:OGO)0:42^3)Q_\^4+X
M8U!W16--+%<Y_?>AJ53B6A,BU:;8IZ?X<^&\Y?INC%6PN&YQ_S$L">=D*O%5
MXELY-+I1>DL-*U<+I;C''#)B'OP4$9]Y(1<>\5WJ53)654NV534,E7-?.YX[
M;/:UUIKC6I6@UE50#^VH=JP(Z!I:NS;'"O_ 3M7"%WKJ%9&J*%M%V=4#B3M^
M$Z3?UO3V:A&EDGDE\S5UV"U=URQSM52^2G TJQMV!;AF539<2=M2?A.BRH;W
M=N)27]=:'05FE<0?2=EPUVAKG>V.A*@ *AZN^RIM;6N'2Q4W'S7Q5;1_ZANV
MC^0+M8[1TOH/'K^HU$>IC_J&[7KM,7M=K6UME6\O80"A#I:JLFDJOP4ZYF.-
M6YK1 =M@MA7,/@8IK6;VV9('GUF=U?"OLM"XW-^AJ* "*^)5^%^-]>C2DJ\D
M_VBIK_9NH5)Y]JO[+\F&2(/1'>;?DJUB;+W[9_'*3]L3!&'EMSLUJI+>3CZ5
ME!ZUE!X:\^XNI-5$MTME5U?P.+1T1KX&V<')TD5JY%>]J>NZ07P:D!OJQFQ
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M%Z(#[C2X1VSJ\XBZE0SO51UZ5>W(D3C(=EOK6:;6ZJP>IZ]DM:ZR6DW79@
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MD_'GQQ8]J&6+O%O'DY(XEB?6][5,7^3R.\H]<CT%KO@L!C:%&OG@V?D\'WZ
MYU\^7WWY^.'B[/KR@EQ=PS^?+C]?7Y$O;\F7KY??SJX_P -['N]FOBY9R"W9
M+(55>HG<:B;&!PRC2_V0#;(?BB-!\Y!J HJT#7=@\A9,(FK7HD645Q;,5<'/
MIL\L^QTB60,Z)'ES@N U&V?:OY',Q#:9Y%;3>G 1O*"SA<8%-#AVQ6TVC=GO
MT@</$E-^"W/VJ(7-[]-1*-PX8D,TMD_E:;<2E.WEI.AA?R[IHC=;K0-R(77A
MLN,5AAP5(XRF:2E&E($1>K/[8$)-<>*9. 'AM^)#"?@ IDGYB#(PHJ\LTUX9
M\7CE0\:1[4+6YZ.ZMPZ*/\LJW6,!8[7F . 4T B0IGVRJY-J-XWV09<M>S\)
MG/_%:$ N/8=M///GT4.@E=8<6FMZ*U.PPV<2<FTP=]4&PVSJ1J6U <^_VM/)
M_(_$KP?A^>K?3R$%1E.WJBX%^E,<?7\ 6_B-W3 O9N'@*5?T#AT5''I]]N'<
M3<VI?RQA\AQ5T(L6[>F(?6J;?IARHX?Q?;W%]S%0?3CI_:'"_.?V+"M'F+HN
M!8=/Y6)ND/J<*D3.I2A]?7X'LJ>O]QY8=W8]*\G2^N9JE4YI(_V2R.AS*^(^
M9+0<YCT]B;W:8&+)Y'^1IW!QSQ8SIK"%PA9/B"UJMRG$,C2]\] F*(572N6)
M2J02_7IJA-G3>KVMSJXLCT,<9ENA%-XY!J>F?%>"GCHMK=]?/4A=H:?:^2SE
MFG[,-54 Q*U='?_Y]7 %]A38J\A"4EG)KZ0;5)BN.FM0^Z&^[(CLBX\[!_$[
M=^S.9UZXH?+A*/Q2^=W//L]4+4.B_^$JA&/P".4W_'OC3SG6EK8L':@ -EE:
M8/K&0D8#>RI/%W+8#7.%/V/>VK/G%?ZH*/YXED,\#Z^FVQX&C\DUT^P_QW&U
ME?0N%<8;3R_I9?!'VPFZJ9GMOF;JK9\\CO; 'NJ=/*;$E0Z*.C/N\3 *Y-8Y
M!3DJZ'%JM\"SM3YVM)[9T?K6F@\5*?12%3=2M]6:K:77T,Q67S/,-:?\5Q,(
MY84%8B69I<!/C<!/F:BOCS,S+*W?-P!*=16,JA^,*A'U]?&@EM;6>YIEZ17#
M8T]4S7 4?O,HW&,UO>"!9Z&2+NTH/%<E'=23U1U4 \G);TR. S'+T)SP%(I3
M*$ZAN$=1'.8DC>Z#7T96*$ZA.(7B[K_6W.UKK=::Y6.%XFKJ-X_"/9:SXD.A
M-(72]H?2JD%D95%8\;0*\B)=37NI#L6K$Q [DEK"^IYU5R[Q+4]E1YT*!*M_
MUMT'/$R6A5'J333BL;4UZ4?A+JKL%2IG_'<\L,'46OVV AZ5-?]5L_([GHFE
M=:QN30#'DL=X*P(&(R+LSIY2;\*(*\)PH]]0^$/AC_JO[W1-K6^NJ3=2.$;A
MF.-9LNEWM%:O:KN@LJ*&$1N#8\N2:A&]4RBHM+YIC^=]UT'OL+J@U]':?;7C
MJ?3^9'_'@-=!<BVM#:&3V:_39B=U(EV)P\<*U@M4;+FGK.17TI]5&#B5B/J*
MUR24Q[NMK!TIK%1Z#U2C%:.MP\J6INL*"Y7>1=1GD6AKR6QK5J^V8$=A&X5M
MCGJK4%FGIY+^2V&?^JPN'0$V@C8_LT@60R@T5%J?]60K1Q;HE"/BD<LJE8#'
MI:.^KG7T-4&I@DOE\BI/M7144='%M:.NUNF9=853:NVH1'&4PE>52:$K_*3P
MDUH[*C$^(CX+2#BE@?J<49G]3[U6CM3GC*J <6JU)%2GSQFM-=^$1E' 1W%$
M$3Q&@MAB-A,>="WL[U. +"P(28.,:,CMY,-'W(TCYBB84B.8LC8M43'@L9=4
M6M-29W37$(P\J7R7P4UM+=YK#B\L.^3XITR?,8=0&!:=L-Q#2?2QK6\Z"A=4
M?D]3(T"RX^$'NF9TVEI+;ZG%FI)[C?H F=U$U=0Z/0,DM;?>99Q*R #_.ORF
M-$*V]ZG\,PXC/IXOC6RT<8'GY/792,01>4>Y1ZZGX+%\%H.PA!KYX-G-3*9&
M1>EZGD%O&!'A(8D"ZH5C$<SPRT[1E!$GB"?@34-;@*C/B4\#ZO#)C-SR: J#
M#6([B@/JNG,201=,>F<7@&4$([-)P":Q2R,!R)$#IV H'!Z0[_((L&<@_( S
M>'..OMP'[(F'D%.WV".\CP,B5Y>7C>L[F*QN:]C$X1.:B %BU;3U.?$8O-4(
M&?,:Z2;@PG"2(88$8@;H.F+<@W%Y-\*]@5'!G$"OC(8PU]0.$!OC!(QCUR6A
MSVR@=4;$&"]F$T<@[J"2C!L8 +3K^R*(8H]'''Z#W@DE@3Q6 ][#F6RDW4)G
M,")JRR/7-=RG[,9H![)AP<Q*XOZ2\Z'EEZ&3Q1OYI-\_,0$.I7<+I'-O"EJ#
MEY-O0M[?P5'<R!>:4E91EXSN$,CB/G.YQX!Z$ J8V3@0T+S\LB1^23*?+HVX
M\U"$()LN9@MD: ;WY+HTW)P!@T$CH*O[^84A" ^#[<E\J5>744D-D#%#GGRE
MP7?@D[A_(FV%3"EN]&9 T"V%KAQ@E2<G,8PE'Y*C[5%0/G%[2IE+_M$D;\4=
M_($')<621ZL]Y-]W?O'I'V_?OI3#Q7:N.$A*$,J)?K01*>7OWIP!&^ 7!E)$
MT]/V4:PN83*!ET'8,,F? L0AIUF^9XM&1LW"*SZC'OG#PU[?BX#_!?^:NJF#
MHA6^2/W!\T08\S!D2&] 9LE>>-2B3)Y<.8-H2B,RC2(_')R>WM[>-B? BH*
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M_S3(BX[1?4E:EM[HMKN=^UN.;.J_7'@W!'"6OKHI$[3_B3 ?7+.I)6,7U*?
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M,#(R,#,R-%]D968N>&UL4$L! A0#%     @ 3$%X5!PB(9+_!0  PD8  !4
M             ( !$@<  &=A;G@M,C R,C S,C1?;&%B+GAM;%!+ 0(4 Q0
M   ( $Q!>%3*5B>%K 0  "(J   5              "  40-  !G86YX+3(P
M,C(P,S(T7W!R92YX;6Q02P$"% ,4    " !,07A44-"\#^@4   FBP  %
M            @ $C$@  9V%N>"TR,#(R,#,R-'@X:RYH=&U02P$"% ,4
M" !,07A4DR$61&\H   OH ( &               @ $])P  9V%N>"TR,#(R
E,#,R-'AE>#DY9#$N:'1M4$L%!@     &  8 D $  .)/      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
